In response to PU-H71 treatment (an HSP90 inhibitor), they observed a dose-dependent decrease in cell growth associated with JAK2 degradation in JAK2V617F cell lines such as UKE-1 and SET-2, in JAK2 and thrombopoietin receptor (MPL or EPOR) mutant transduced cells (JAK2K539L; hMPLW515L), and also in primary MPN patient samples (JAK2V617F PV). Here, JAK2 is linked to myeloproliferative disorder.